Published study in

发表于

Cancers

癌症

highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate

凸显了以TransCode公司的领先候选药物靶向microRNA-10b在骨转移治疗中的潜力

BOSTON

波士顿

,

，

Aug. 31, 2026

2026年8月31日

/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:

/PRNewswire/ -- TransCode Therapeutics, Inc.（纳斯达克股票代码：

RNAZ

RNAZ

), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a peer-reviewed article in

），一家处于临床阶段、率先开发用于治疗和高风险及晚期癌症的免疫肿瘤学和RNA基疗法的公司，今天宣布在同行评审期刊上发表了一篇文章

Cancers

癌症

titled,

标题为，

'Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics.'

“在乳腺癌骨定植模型中使用图像引导的核酸靶向疗法针对miR-10b。”

The study reports that TransCode's lead therapeutic candidate, TTX-MC138, produced significant survival benefits in a preclinical model of breast cancer bone metastasis while demonstrating favorable tolerability and no observed systemic toxicity.

研究报告称，TransCode的主要候选治疗药物TTX-MC138在乳腺癌骨转移的临床前模型中显示出显著的生存获益，同时表现出良好的耐受性，且未观察到全身毒性。

The publication builds on a growing body of evidence supporting microRNA-10b (miR-10b) as an important driver of cancer metastasis and further validates TransCode's therapeutic approach of inhibiting miR-10b using proprietary oligonucleotide nanotechnology.

该出版物建立在越来越多的证据基础上，这些证据支持微小RNA-10b（miR-10b）作为癌症转移的重要驱动因子，并进一步验证了TransCode利用其专有寡核苷酸纳米技术抑制miR-10b的治疗策略。

The study was led by Dr. Anna Moore, Professor in the Radiology and Physiology Departments, Director of the Precision Health Program and Associate Dean for Research Development at the College of Human Medicine at Michigan State University. Dr. Moore is a co-founder of TransCode Therapeutics and Chair of the Scientific Advisory Board, and a globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics..

该研究由安娜·摩尔博士领导，她是密歇根州立大学人类医学院放射学和生理学教授、精准健康项目主任以及研究发展副院长。摩尔博士是TransCode Therapeutics的联合创始人兼科学顾问委员会主席，也是分子成像和RNA靶向癌症治疗领域的全球公认专家。

'Metastatic disease remains responsible for the overwhelming majority of cancer deaths, and effective therapies specifically designed to target metastasis remain limited,' said Zdravka Medarova, Ph.D., Chief Scientific Officer of TransCode Therapeutics and co-author of the publication. 'These findings demonstrate that miR-10b inhibition can significantly impact survival in a challenging model of metastatic cancer and further support the potential applicability of our platform across multiple metastatic tumor types.'.

“转移性疾病仍然是导致绝大多数癌症死亡的原因，而专门针对转移的有效疗法仍然有限，”TransCode Therapeutics 首席科学官、该论文的共同作者 Zdravka Medarova 博士表示。“这些研究结果表明，在具有挑战性的转移性癌症模型中，抑制 miR-10b 可以显著影响生存率，并进一步支持我们的平台在多种转移性肿瘤类型中的潜在适用性。”

Key Findings

主要发现

Among the study's findings:

研究的发现包括：

TTX-MC138 successfully accumulated in metastatic bone lesions in a mouse model of bone cancer bone metastasis following systemic administration.

在骨癌骨转移小鼠模型中，TTX-MC138经全身给药后成功在转移性骨病灶中蓄积。

Treatment significantly reduced expression of miR-10b, a microRNA implicated in metastatic progression, and increased expression of HOXD10, a downstream tumor-suppressor target.

治疗显著降低了与转移进展相关的微小RNA miR-10b的表达，并增加了其下游肿瘤抑制靶点HOXD10的表达。

Animals treated with anti-miR-10b therapeutics demonstrated significant survival benefits compared with controls.

与对照组相比，接受抗miR-10b疗法治疗的动物表现出显著的生存获益。

Repeated dosing was well tolerated, with no evidence of systemic toxicity observed during the study.

重复给药耐受性良好，研究期间未观察到全身毒性证据。

The results support the use of image-guided anti-miR-10b nanotherapeutics as a potentially translatable strategy for treating metastatic cancer.

研究结果支持将图像引导的抗miR-10b纳米药物作为一种具有潜在临床转化前景的治疗转移性癌症的策略。

Bone is the most common site of metastatic spread in breast cancer and represents a major unmet medical need, with patients experiencing substantial morbidity and poor long-term outcomes. The authors concluded that targeting miR-10b using an image-guided anti-miR-10b nanotherapeutic represents a promising and translatable strategy for treating breast cancer bone metastases..

骨是乳腺癌转移最常见的部位，构成了一个重大的未满足医疗需求，患者遭受显著的病痛负担且长期预后不良。作者得出结论，利用影像引导的抗miR-10b纳米疗法靶向miR-10b，是一种治疗乳腺癌骨转移的具有前景且可转化的策略。

Relevance to TransCode's Clinical Program

与 TransCode 临床项目的相关性

While TransCode's current clinical development efforts are focused on metastatic cancers and its ongoing TTX-MC138 program in molecular residual disease-positive colorectal cancer, the newly published findings suggest potential future applicability of miR-10b inhibition across additional metastatic disease settings where tumor spread drives poor outcomes..

尽管TransCode目前的临床开发工作主要集中在转移性癌症以及其正在进行的针对分子残留病灶阳性的结直肠癌的TTX-MC138项目上，但新发表的研究结果表明，抑制miR-10b在未来可能适用于更多因肿瘤扩散导致不良预后的转移性疾病场景。

The article was published online on August 23, 2026, in Cancers, a peer-reviewed oncology journal.

该文章于2026年8月23日在线发表在同行评审的肿瘤学期刊《Cancers》上。

About TTX-MC138

关于 TTX-MC138

TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers. TransCode's Phase 1a first-in-human clinical trial achieved its primary safety endpoint and established a recommended Phase 2 dose, as announced at ESMO 2025..

TTX-MC138 是一款首创的治疗候选药物，旨在抑制 microRNA-10b（miR-10b）。miR-10b 被广泛认为对多种转移性癌症的发生和进展至关重要。TransCode 的 Phase 1a 首次人体临床试验达到了主要安全性终点，并确定了推荐的 Phase 2 剂量，这一成果已在 2025 年欧洲肿瘤内科学会（ESMO）大会上公布。

About TransCode Therapeutics

关于 TransCode Therapeutics

TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.

TransCode Therapeutics 是一家处于临床阶段的生物制药公司，致力于开创针对高危和晚期癌症的免疫肿瘤学和 RNA 疗法。公司的主要候选药物 TTX-MC138 专注于治疗过度表达 microRNA-10b 的转移性肿瘤，microRNA-10b 是一种独特且文献记载充分的转移生物标志物。

In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For more information, visit .

此外，TransCode 还拥有其他同类首创的治疗候选产品组合，旨在动员免疫系统识别并摧毁癌细胞。欲了解更多信息，请访问 。

www.transcodetherapeutics.com

www.transcodetherapeutics.com

.

。

Forward-Looking Statements

前瞻性陈述

This release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the potential significance of the preclinical findings described in the publication and the therapeutic potential of targeting microRNA-10b with TTX-MC138 across multiple metastatic tumor types.

本次发布包含1995年《私人证券诉讼改革法案》所指的“前瞻性陈述”，包括但不限于有关所述临床前发现的潜在重要性以及通过TTX-MC138靶向microRNA-10b在多种转移性肿瘤类型中的治疗潜力的陈述。

Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

本新闻稿中的任何前瞻性陈述均基于管理层对当前未来事件的预期，并受多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性陈述中明示或暗示的结果存在重大且负面的差异。

These risks and uncertainties include, but are not limited to: the risks associated with drug discovery and development; the risk that the results of clinical trials will not be consistent with TransCode's preclinical studies or expectations or with results from previous clinical trials; risks associated with the conduct of clinical trials; risks associated with TransCode's financial condition and its need to obtain additional funding to support its business activities, including TransCode's ability to continue as a going concern; risks associated with the timing and outcome of TransCode's planned regulatory submissions; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode's ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; risks of competition from other companies developing products for similar uses; risks associated with TransCode's dependence on third parties; and risks associated with geopolitical events and pandemics.

这些风险和不确定性包括但不限于：与药物发现和开发相关的风险；临床试验结果与TransCode的临床前研究或预期不符，或与以往临床试验结果不一致的风险；与开展临床试验相关的风险；与TransCode的财务状况及其为支持业务活动而需获得额外融资的需求相关的风险，包括TransCode持续经营的能力；与TransCode计划进行的监管申报的时间和结果相关的风险；与获取、维持和保护知识产权相关的风险；与TransCode对侵权者执行其专利权以及抵御第三方对其专利组合提出的挑战的能力相关的风险；来自其他开发类似用途产品的公司的竞争风险；与TransCode依赖第三方相关的风险；以及与地缘政治事件和流行病相关的风险。

For a discussion of these and other risks an.

有关这些风险及其他风险的讨论。

SOURCE TransCode Therapeutics, Inc.

来源：TransCode Therapeutics, Inc.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示